Do These Stocks Offer Stable Returns? Capitol Acquisition Corp II (CLAC) and NovaBay Pharmaceuticals Inc (NBY)

Posted by Saimoon April 20, 2015 0 Comment 416 views


New York, NY – GDP INSIDER  –  04/20/2014.

This article discusses two companies: Capitol Acquisition Corp II (NASDAQ:CLAC) and NovaBay Pharmaceuticals Inc (NYSEMKT:NBY)

Capitol Acquisition Corp II (NASDAQ:CLAC) made further gains yesterday with the stock climbing an additional 10.73% or $1.10 to close at $11.35 with more than 2.605 million shares changing hands, compared to its three month average trading volume of 0.031 million. The merger, acquisition and share exchange specialist service provider has been creeping up for a while now. In fact the stock is now significantly outperforming the S&P 500, as the share price has gained 14.88% so far this year, compared to the S&P 500 which has only managed a modest 0.85% gain over the same period. With diluted EPS of -$0.16 and a current ratio of 0.14 the fundamentals are relatively weak, but the technical indicators tell a different story. The stock has a positively diverging MACD and RSI of 89.68 which could indicate that it is trading higher. However, with the data so conflicted it is a better sell than buy at this time.
Is Capitol Acquisition Corp II Ready For Medium Term Investment? Read Our Free CLAC Investment Analysis To Make A Wise Investment Decision.

NovaBay Pharmaceuticals Inc (NYSEMKT:NBY) continued its upward trend on Friday with the stock gaining another 1.20% or $0.01 to close at $0.84 on low trading volume of 0.157 million shares, compared to its three month average trading volume of 0.285 million after it signed a nationwide distribution agreement with AmerisourceBergen to distribute Avenova to retail chain pharmacies across the United States. The clinical stage biotechnology company focused on developing anti-infective compounds to treat infection has been gaining ever since it released very positive fourth quarter and full year results at the end of March. The company is pursuing an aggressive sales strategy and has more than doubled its sales force promoting its flagship product Avenova. The stock had been underperforming the S&P 500 for most of this year so far, but its recent gains have propelled the stock price to a gain of 33.33% YTD. The RSI of 61.47 indicates the stock is not overvalued at the current levels, the MFI of 74.27 shows the money is flowing in the right direction, making it a hold for now.

Is NovaBay Pharmaceuticals Inc Overvalued? Take A Look At The Technical Indicators In Our Free NBY Analysis.

About Ultimate Stock Alerts

UltimateStockAlerts.com covers NASDAQ and NYSE listed companies that are overlooked by Wall Street. Investors can choose to receive trading strategies via text message (SMS) or email. To receive free text message alerts text the word ULTIMATE to 555888 from your cell phone. For more information visit www.UltimateStockAlerts.com

Disclosure:  UltimateStockAlerts.com is not a registered investment adviser and nothing contained in any materials should be construed as a recommendation to buy or sell securities. Investors should always conduct their own due diligence with any potential investment. Please visit www.UltimateStockAlerts.com website, for complete risks and disclosures.


Write Your Comment